Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Alex F. Herrera, Yazeed Samara et al.|Haematologica|2022Cited by 73
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter AnalysisAdam S. Kittai, Alexey V. Danilov, Brian T. Hill et al.|Transplantation and Cellular Therapy|2020Cited by 60
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Thomas Ollila et al.|Blood Advances|2022Cited by 50
Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.Lindsey Fitzgerald, Boyu Hu, Alexandra Waller et al.|Journal of Clinical Oncology|2020Cited by 19